B-Cell Therapies in Multiple Sclerosis.

Area of Science:

• Neuroimmunology
• Immunology
• Neurology

Background:

• B cells are integral to the pathogenesis of multiple sclerosis (MS).
• Current MS therapies modulate B cell frequency, phenotype, or homing.
• B-cell-depleting therapies targeting CD20 have shown significant clinical efficacy.

Purpose of the Study:

• To highlight the critical role of B cells in MS.
• To underscore the impact of B-cell-targeting therapies in MS management.
• To provide a basis for developing novel therapies focused on specific pathogenic B cell populations.

Main Methods:

• Review of clinical trial data for anti-CD20 monoclonal antibodies.
• Analysis of the immunological mechanisms underlying B cell involvement in MS.
• Evaluation of the therapeutic effects of Ocrelizumab in relapsing and primary progressive MS.

Main Results:

• Ocrelizumab demonstrated substantial reductions in inflammatory disease activity in relapsing MS.
• Ocrelizumab showed a significant slowing of disability progression in primary progressive MS.
• These findings confirm B cells as a central target in the MS inflammatory cascade.

Conclusions:

• B cells are key players in multiple sclerosis pathogenesis.
• Targeting B cells, particularly with anti-CD20 therapies, is an effective strategy for MS treatment.
• Further research into selective B cell targeting holds promise for future MS therapies.